J9371 – Injection, vincristine sulfate liposome, 1 mg
HCPCS Level II code · J codes: Drugs Administered Other Than Oral Method
HCPCS codeJ9371
- Long description
- Injection, vincristine sulfate liposome, 1 mg
- Short description
- Inj, vincristine sul lip 1mg
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1DChemotherapy- Added
- January 1, 2014
- Last change
- July 1, 2024 – No change
- Termination date
- June 30, 2024
Frequently asked questions
What is HCPCS code J9371?
J9371 is a HCPCS Level II code for injection, vincristine sulfate liposome, 1 mg. It was discontinued on June 30, 2024.
Does Medicare cover J9371?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby J codes
- J9356 – Injection, trastuzumab, 10 mg and hyaluronidase-oysk
- J9357 – Injection, valrubicin, intravesical, 200 mg
- J9358 – Injection, fam-trastuzumab deruxtecan-nxki, 1 mg
- J9359 – Injection, loncastuximab tesirine-lpyl, 0.075 mg
- J9360 – Injection, vinblastine sulfate, 1 mg
- J9361 – Injection, efbemalenograstim alfa-vuxw, 0.5 mg
- J9362 – Injection, trabectedin, 0.01 mg
- J9370 – Vincristine sulfate, 1 mg
- J9376 – Injection, pozelimab-bbfg, 1 mg
- J9380 – Injection, teclistamab-cqyv, 0.5 mg
- J9381 – Injection, teplizumab-mzwv, 5 mcg
- J9382 – Injection, zenocutuzumab-zbco, 1 mg
- J9390 – Injection, vinorelbine tartrate, 10 mg
- J9393 – Injection, fulvestrant (teva), not therapeutically equivalent to j9395, 25 mg
- J9394 – Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg
- J9395 – Injection, fulvestrant, 25 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.